Tag Archives: Federal Circuit

UCB, Inc. v. Accord Healthcare, Inc. – Can a Racemic Mixture be a “Lead Compound.”

UCB v. Accord, Appeal no. 2016-2610 et al. (Fed. Cir., May 23, 2018) may be headed to the Supreme Court, which prompted me to take another look at this opinion. This was a decision in Hatch-Waxman litigation, in which a … Continue reading

Posted in Obviousness | Tagged , , , , , , , , , | Leave a comment

Phillips Standard of Claim Construction to be Used by PTAB in “AIA Proceedings”

After much deliberation, the USPTO has published a Final Rule mandating that the claim construction standard articulated by the Fed. Cir. in Phillips v. AWH Corp., 415 F.3d 1301 (Fed. Cir. 2005), and used by federal district courts, will replace … Continue reading

Posted in PTAB | Tagged , , , , , , , , | Leave a comment

Roche Molecular Systems, Inc. v. Cepheid – Are Primers “Natural Products”?

Anyone familiar with the fate of claims to primers used in PCR, to amplify a stretch of target DNA in order to determine whether or not a significant mutation is present, could write the opinion in this appeal (No. 2017-1690 … Continue reading

Posted in Section 101 | Tagged , , , , , , , , , , | 1 Comment

Ex parte Parenteau – PTAB Skips Step One of the Mayo/Alice Test?

In ex parte Ho, the subject of my last post, the PTAB reversed the Examiner’s rejection of claims to a population of bone marrow cells obtained by two-stage culturing that expressed or failed to express certain markers. The PTAB wrote … Continue reading

Posted in Section 101, Section 103 | Tagged , , , , , , , , | Leave a comment